Higher GJB2 expression in differentiated cells was characteristic of IDH-wildtype GBMs with worse prognosis (Johnson et al, 2021), while reduced GJB2 expression and enrichment of stem-like cells was apparent in IDH-mutant gliomas with improved prognosis (Cohen et al, 2013). The gene discussed is GJB2; the disease is glioma.